BR112017016497A2 - composições e métodos para metabolismo muscular melhorado - Google Patents

composições e métodos para metabolismo muscular melhorado

Info

Publication number
BR112017016497A2
BR112017016497A2 BR112017016497A BR112017016497A BR112017016497A2 BR 112017016497 A2 BR112017016497 A2 BR 112017016497A2 BR 112017016497 A BR112017016497 A BR 112017016497A BR 112017016497 A BR112017016497 A BR 112017016497A BR 112017016497 A2 BR112017016497 A2 BR 112017016497A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
extract
muscle metabolism
improved muscle
Prior art date
Application number
BR112017016497A
Other languages
English (en)
Other versions
BR112017016497B1 (pt
Inventor
Charles Bily Antoine
Chevalier Karl
Denise Falcao Leila
Laurencon Lise
Roller Marc
Meyer Marjolaine
Feuillere Nicolas
Elizabeth Renée Fança-Berthon Pascale
Birtic Simona
Original Assignee
Naturex Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naturex Sa filed Critical Naturex Sa
Publication of BR112017016497A2 publication Critical patent/BR112017016497A2/pt
Publication of BR112017016497B1 publication Critical patent/BR112017016497B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uma composição para melhorar metabolismo muscular num sujeito e métodos para fabricar e usar a mesma. modalidades incluem composições tendo um extrato de rhaponticum e um extrato de rhodiola. um extrato de rhaponticum pode incluir quantidades de ecdiesteronas incluindo 20-hidroxiecdisona. um extrato de rhodiola pode incluir salidrosidas e rosavinas, incluindo rosavina. dosagens de ingestão adequadas da composição podem ser operáveis para aumentar a síntese de proteína e reduzir proteólise de proteína num sujeito.
BR112017016497-3A 2015-02-03 2016-02-03 Composições e métodos para metabolismo muscular melhorado BR112017016497B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/612,973 2015-02-03
US14/612,973 US9700589B2 (en) 2015-02-03 2015-02-03 Compositions and methods for improved muscle metabolism
PCT/IB2016/000322 WO2016125025A1 (en) 2015-02-03 2016-02-03 Compositions and methods for improved muscle metabolism

Publications (2)

Publication Number Publication Date
BR112017016497A2 true BR112017016497A2 (pt) 2018-04-10
BR112017016497B1 BR112017016497B1 (pt) 2021-03-30

Family

ID=55806552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016497-3A BR112017016497B1 (pt) 2015-02-03 2016-02-03 Composições e métodos para metabolismo muscular melhorado

Country Status (12)

Country Link
US (2) US9700589B2 (pt)
EP (1) EP3253399B1 (pt)
JP (1) JP6726196B2 (pt)
KR (1) KR102520312B1 (pt)
CN (1) CN107624069A (pt)
AU (1) AU2016214079B2 (pt)
BR (1) BR112017016497B1 (pt)
CA (1) CA2975497C (pt)
CO (1) CO2017007874A2 (pt)
MX (1) MX2017009929A (pt)
RU (1) RU2730853C2 (pt)
WO (1) WO2016125025A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3065644B1 (fr) * 2017-04-28 2020-02-21 Biophytis Extrait de 20-hydroxyecdysone de qualite pharmaceutique, son utilisation et sa preparation
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
FR3093640B1 (fr) * 2019-03-15 2021-10-01 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires
CN113367337B (zh) * 2020-03-10 2023-02-24 晨光生物科技集团股份有限公司 一种包含槲皮万寿菊素的组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000781C1 (ru) * 1992-04-29 1993-10-15 Научно-производственное объединение "Алтай" Лосьон дл кожи лица
RU2066963C1 (ru) 1993-10-20 1996-09-27 Рошен Джафарович Сейфулла Натуральный поливитаминный комплекс "леветон"
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
RU2174397C1 (ru) 2000-06-02 2001-10-10 Институт нефтехимии и катализа АН республики Башкортостан и Уфимского научного центра РАН Способ получения концентрата экдистероидов и экдистерона из растительного сырья
RU2259840C2 (ru) * 2003-11-14 2005-09-10 Институт общей и экспериментальной биологии СО РАН Лекарственное средство, обладающее адаптогенной активностью
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
RU2321420C1 (ru) * 2006-07-20 2008-04-10 Институт биологии Коми научного центра Уральского отделения Российской академии наук Средство "экдистерон-80", обладающее кардиопротекторной, адаптогенной, антигипоксической, гастропротекторной, термопротекторной, анаболической и актопротекторной активностью, и способ его производства
US7906159B2 (en) 2008-04-17 2011-03-15 Vivien Chou Herbal compositions and methods for enhancing vital energy and athletic performance
RU2390270C1 (ru) 2009-03-13 2010-05-27 Общество С Ограниченной Ответственностью "Парафарм" Биологически активная добавка к пище
US8343946B2 (en) 2009-07-27 2013-01-01 Thermolife International, Llc Ecdysterone compounds
WO2012054993A1 (en) * 2010-10-26 2012-05-03 Vasil Petrov Terezov Composition for food supplement and method for manufacturing thereof
FR2983733B1 (fr) 2011-12-13 2017-12-22 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans l'amelioration de la qualite musculaire de mammiferes obeses et/ou sarcopeniques
CN102631573B (zh) * 2012-04-03 2013-12-25 迟华群 一种治疗溲赤型红丝疔的中药洗剂制备方法
CN102631577B (zh) * 2012-04-03 2013-09-18 刘宪荣 一种治疗溲赤型足底疔的中药洗剂制备方法
CN102727505A (zh) * 2012-07-09 2012-10-17 中国航天员科研训练中心 红景天苷在防治肌萎缩疾病中的应用
CN102727560B (zh) 2012-07-09 2014-07-09 中国航天员科研训练中心 红景天在预防和治疗肌萎缩疾病中的应用
JP2014015429A (ja) * 2012-07-10 2014-01-30 Kao Corp サテライト細胞分化促進剤
CN103432452A (zh) * 2013-08-22 2013-12-11 韩增禄 一种治疗嗜食辣椒型急性颈部***炎的中药制备方法

Also Published As

Publication number Publication date
US10258658B2 (en) 2019-04-16
US20160220624A1 (en) 2016-08-04
KR102520312B1 (ko) 2023-04-12
CO2017007874A2 (es) 2017-10-20
EP3253399A1 (en) 2017-12-13
RU2017127509A (ru) 2019-03-04
JP2018505892A (ja) 2018-03-01
US9700589B2 (en) 2017-07-11
CA2975497C (en) 2023-08-01
CA2975497A1 (en) 2016-08-11
KR20180011755A (ko) 2018-02-02
AU2016214079B2 (en) 2021-04-01
CN107624069A (zh) 2018-01-23
EP3253399B1 (en) 2021-10-13
JP6726196B2 (ja) 2020-07-22
MX2017009929A (es) 2018-04-10
BR112017016497B1 (pt) 2021-03-30
US20170296605A1 (en) 2017-10-19
RU2017127509A3 (pt) 2019-08-29
WO2016125025A1 (en) 2016-08-11
RU2730853C2 (ru) 2020-08-26
AU2016214079A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
BR112018006368A2 (pt) composição para desempenho melhorado
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
BR112019006463A2 (pt) composição oral de canabinoides extraídos e métodos de uso da mesma
AR115585A1 (es) Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
BR112018017228A2 (pt) composições e métodos para regeneração do músculo usando prostaglandina e2
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal

Legal Events

Date Code Title Description
B25H Request for change of headquarter rejected

Owner name: NATUREX SA (FR)

B25H Request for change of headquarter rejected

Owner name: NATUREX SA (FR)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870170081799 DE 25/10/2017, POR NAO SE REFERIR AO DEPOSITANTE DO PEDIDO COM FUNDAMENTACAO NO ART. 59 DA LPI.

Owner name: NATUREX SA (FR)

B25H Request for change of headquarter rejected

Owner name: NATUREX SA (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2016, OBSERVADAS AS CONDICOES LEGAIS.